Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identify Prognostic Biomarkers of Lung Cancer

NCT05010330

Lung Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma +1 more

UNKNOWN

Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer

NCT05425134

Non-small Cell Lung Cancer

UNKNOWN

Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer

NCT04553601

NSCLC PET/CT Biopsy +3 more

UNKNOWN NA

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

NCT03059641

Lung Neoplasms Lung Cancer, Nonsmall Cell Adenocarcinoma of Lung +1 more

COMPLETED

99mTc-H7ND SPECT/CT Imaging in NSCLC

NCT05999214

NSCLC

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Neoadjuvant pemetrexed and cisplatin chemotherapy

Intervention Type OTHER

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neoadjuvant pemetrexed and cisplatin chemotherapy

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Aged between 18 and 75 years;
* 2\. Lung adenocarcinoma;
* 3\. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
* 4 .The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion Criteria

* 1\. Patients with a history of lung surgery;
* 2\. Postoperative pathology showed non-primary lung cancer;
* 3\. Patients with a history of other tumors;
* 4\. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
* 5\. Unable to cooperate with the researchers because of dementia or cognitive decline
* 6\. Other situations that are not in conformity with the standards and requirements of this trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No